Results 1 to 10 of about 35,157 (145)

Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases [PDF]

open access: yesScientific Reports
Lanreotide and Octreotide are used to treat various endocrine and neoplastic diseases. This study aims to compare the adverse event profiles of Lanreotide and Octreotide in somatostatin-responsive diseases using FAERS data.
Le Wang   +3 more
doaj   +2 more sources

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. [PDF]

open access: yesPLoS ONE, 2012
Octreotide is a widely used synthetic somatostatin analogue that significantly improves the management of neuroendocrine tumours (NETs). Octreotide acts through somatostatin receptors (SSTRs).
Su-Chen Li   +8 more
doaj   +5 more sources

Octreotide in the therapy of recurrent medulloblastomas [PDF]

open access: yesArchive of Oncology, 2006
BACKGROUND: Recurrence of medulloblastoma appears after 30% to 40% of the surgeries. Different from primary medulloblastoma, in which five-year survival rate is 50%, the survival time of relapses much shorter and only 20% of the patients manage to ...
Stefanović Ivan   +3 more
doaj   +3 more sources

Use of octreotide for prevention of pancreatic leak after pancreatoduodenectomy: study progress [PDF]

open access: yesWaike lilun yu shijian, 2022
The pancreatic leak after pancreaticoduodenectomy was one of the main causes of postoperative death, the rate of which remained high. Octreotide, an octapeptide somatostatin analogue, has been used in the prevention and treatment of postoperative ...
XU Yu, ZHANG Junfeng, HUA Rong
doaj   +1 more source

Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs

open access: yesPathophysiology, 2023
Acromegaly is a condition most commonly diagnosed in the fifth decade of life and has numerous treatment options. In this regard, Mycapssa® is the first FDA-approved oral octreotide capsule for treating acromegaly, combining the efficacy of the ...
Charles P. Daniel   +9 more
doaj   +1 more source

Effect of Octreotide Injection on Postoperative Drainage After Neck Dissection: A Preliminary Report of a Prospective, Matched Case-Control Study [PDF]

open access: yesClinical and Experimental Otorhinolaryngology, 2016
Objectives Somatostatin inhibits lymph production and reduces lymph flow into the lymphatic duct. We hypothesized that octreotide, a long-acting somatostatin analog, would reduce drainage after neck dissection (ND) by reducing the overall lymphatic flow ...
Dongbin Ahn   +3 more
doaj   +1 more source

Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy

open access: yesМедицинский совет, 2022
Octreotide is a first-generation somatostatin analog that has been used for 40 years for the medical treatment of acromegaly, both after neurosurgical intervention and as first-line treatment.
I. A. Ilovayskaya
doaj   +1 more source

Parahydrogen-induced polarization allows 2000-fold signal enhancement in biologically active derivatives of the peptide-based drug octreotide

open access: yesScientific Reports, 2023
Octreotide, a somatostatin analogue, has shown its efficacy for the diagnostics and treatment of various types of cancer, i.e., in octreotide scan, as radio-marker after labelling with a radiopharmaceutical.
Jonas Lins   +10 more
doaj   +1 more source

Current diagnosis and treatment of acute pancreatitis in China: a real-world, multicenter study

open access: yesBMC Gastroenterology, 2021
Background Efficacy of pancreatic enzyme inhibitors in acute pancreatitis (AP) is unclear in China. Aims We aimed to present the current status of AP and evaluate the efficacy of pancreatic enzyme inhibitors in a larger population in China.
Chuandong Sun   +3 more
doaj   +1 more source

Uneventful octreotide LAR therapy throughout three pregnancies, with favorable delivery and anthropometric measures for each newborn: a case report

open access: yesJournal of Medical Case Reports, 2011
Introduction The safety of octreotide use, in its short-acting preparation, in pregnancy is still unclear. This report provides the first documentation of uneventful octreotide LAR use during three pregnancies in a woman with bronchial carcinoid ...
Naccache Deeb   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy